Figure 3.

Effects of liraglutide treatment on cardiac volumes, oxygen consumption, and power. A: Dobutamine administration resulted in similar and significant decreases in EDV in both saline- and liraglutide-treated animals. B: CO exhibited a similar decrease with dobutamine administration in liraglutide- but not saline-treated animals. C: PVA similarly decreased in liraglutide-treated animals only. D: Cardiac power, however, was significantly greater on average in liraglutide-treated animals relative to saline controls. Values are mean ± SE for saline (n = 5) and liraglutide (n = 7). Displayed P values denote the overall treatment group comparison for differences in response to dobutamine. *P < 0.05 comparing individual doses against baseline within the treatment group (significant in panel C only for the liraglutide-treated animals). †P < 0.05 comparing the treatment groups under resting conditions.